Recently, a group of non-BRCA1/2, moderate- to high-risk breast cancer susceptibility genes, have been observed. Among them, the most prevalent ones are ATM, CHEK2 and PALB2.^1-3 These pathogenic variants (PVs) can increase the risk of breast cancer by at least 2-fold, thus indicating an obvious and urgent need for screening them.^1,3 However, optimal strategies for screening in women carrying these PVs have yet to be well established.¹ In a recent study published in the Journal of the American Medical Association (JAMA), Lowry K P and his colleagues conducted a comparative simulation modeling analysis to determine whether screening using mammography and magnetic resonance imaging (MRI) could benefit breast cancer patients with ATM, CHEK2 and PALB2 PVs at various age intervals, which may increase the survival rate in these female patients.¹

Patients with chronic kidney disease (CKD) display a strong association with atherosclerotic cardiovascular disease (ASCVD) as compared with the general population.^1-3 To date, there are no ASCVD risk prediction models to identify optimal treatments and prevention therapies for this high-risk population of CKD.¹ A recent study published by Bundy and colleagues in the Journal of the American Society of Nephrology, developed and validated 10-year ASCVD risk prediction models among CKD patients, which included novel kidney and cardiac biomarkers to improve the prediction performance and clinical outcomes.¹

In young children, lower respiratory tract infections, such as pneumonia and bronchiolitis, are mainly caused by respiratory syncytial virus (RSV).¹ Nirsevimab is a recombinant human IgG1 kappa monoclonal antibody that interlocks with the RSV fusion (F) protein (binds to F1 and F2 subunits) in its prefusion conformation to prevent viral entry into host cells.² Infants who have received a single intramuscular injection of nirsevimab before the RSV season are protected from RSV-associated lower respiratory tract infection.²

Patients with chronic kidney disease (CKD) display a strong association with atherosclerotic cardiovascular disease (ASCVD) as compared with the general population.^1-3 To date, there are no ASCVD risk prediction models to identify optimal treatments and prevention therapies for this high-risk population of CKD.¹ A recent study published by Bundy and colleagues in the Journal of the American Society of Nephrology, developed and validated 10-year ASCVD risk prediction models among CKD patients, which included novel kidney and cardiac biomarkers to improve the prediction performance and clinical outcomes.¹

Approximately 50% of patients with metastatic castration-resistance prostate cancer (mCRPC) receive only 1 line of active therapy with a median survival of less than 2 years.¹ Hence, there is an urgent need to improve patient outcomes in the first-line mCRPC treatment setting.¹ In the PROpel phase 3 trial, the administration of olaparib and abiraterone combination in mCRPC patients, irrespective of homologous recombination repair gene mutation (HRRm) status, has achieved statistically significant and clinically meaningful improvements in radiographic progression-free survival (rPFS) than abiraterone monotherapy alone.